Lung cancer is the foremost cause of cancer-related deaths world-wide. Both, the major
forms of lung cancer, Non-small cell lung cancer (NSCLC) and Small cell lung cancers …

In past decades, studies focusing on new chemotherapeutic agents for patients with
inoperable non-small-cell lung cancer have reported only modest gains in survival. These …

The growing risk of antimicrobial resistance besides the continuous increase in the number
of cancer patients represents a great threat to global health, which requires intensified efforts …

Introduction Lung cancer, the most prevalent malignant cancer in the world, remains a
serious threat to public health. Recently, a large number of studies have shown that an …

A new series of pyridothienopyrimidine derivatives was designed and evaluated as
antimicrobial and anticancer agents. The target compounds were synthesized starting with 3 …

Background: There are few data on the cost-effectiveness of second-line chemotherapies for
non-small cell lung cancer (NSCLC). The objective of this phase III, randomized, multicenter …

As a result of improved effectiveness of first-, second-line and maintenance therapeutic
regimens in non-small cell lung cancer, there is need for new options as third-line treatment …

Background Posterior capsule opacification (PCO) is the most frequent complication after
cataract surgery, leading to a loss of sight if untreated. Erlotinib might be of therapeutic …

Introduction: Erlotinib was recently approved in British Columbia (BC) as a second-line
treatment for advanced NSCLC. A cost-effectiveness analysis was conducted which …

Abstract Introduction Approximately 80–85% of lung cancer patients are diagnosed with non-
small-cell lung cancer (NSCLC), of which 50% of patients present with advanced or …